AI news ·
Ro Launches AI Healthcare Research Unit for Drugmakers
Ro is launching an AI lab to study patient outcomes and sell the findings to drugmakers, raising concerns about consent and data privacy.
Telehealth company Ro is forming an artificial intelligence research unit designed to analyze patient outcomes and sell the resulting insights to pharmaceutical companies. The initiative is structured to accelerate the generation of clinical evidence for drugmakers.
The new lab raises immediate legal questions regarding patient consent, data privacy, and the commercial rights associated with health information. The company’s move places it at the intersection of healthcare delivery and data brokerage, where regulatory frameworks continue to evolve.